NUTX Heads Into Earnings With 14% Short Float and Bears Circling

Nutex Health reports today with a meaningful short position still in place — but the real story heading into this print is how much bears have already reduced their exposure, even as the stock has given back more than a fifth of its value over the past month.

Short interest runs at 14.3% of the free float, which remains elevated by any standard. Yet the trend is firmly down: shorts have trimmed their position by roughly 10% over the past 30 days, and the borrow market has loosened considerably. Availability has climbed to 55.7% — up nearly 80% week-on-week — and borrowing costs have fallen by a third over the past month to less than 1% annually. That combination signals bears reducing conviction rather than pressing a new bet. The ORTEX short score sits at 78.1, near the top 2nd percentile of the universe, confirming the position is still sizeable — but the direction of travel matters as much as the level.

The bull-bear debate turns on which revenue stream investors decide to believe in. The bear case is stark: arbitration-related revenue fell 26% sequentially to $105 million in Q1, missing estimates and raising doubts about whether those volumes are structurally sustainable. EPS collapsed from $11.12 in Q4 to $2.56, a reminder of how volatile the model can be. The bull case points elsewhere — patient revenue per visit surged 37% year-on-year, gross margins expanded to 56% from 15%, and the company keeps growing its core clinical operations. Analysts with fresh coverage are firmly in the bull camp: B. Riley Securities initiated at Buy with a $290 target in late June, and Lake Street came in at $235 on a Buy a week earlier. The consensus mean target of $246 sits well above the current price of $151.93, implying more than 60% upside on the Street's estimates. Benchmark has held a $300 target through multiple quarters. None of the covering analysts have a Sell.

Ownership adds another layer of concentration risk. Thomas Vo, the founder and Chairman/CEO, holds 30.6% of shares — a position that grew by more than 259,000 shares in the most recent filing. Pertento Partners added 361,000 shares in one quarter to reach a 5.9% stake. BlackRock and American Century also added meaningfully in recent periods. With roughly two-thirds of the float in concentrated or institutional hands, the 14% short interest represents a meaningful fraction of freely traded shares — which is why the days-to-cover figure of 7.6 days matters if sentiment shifts quickly.

The past two prints offer a divergent picture: the stock rose 5% the day after Q2 results in late July, then extended those gains to 8% over the following week. The prior quarter saw a one-day drop of nearly 6%. Today's report therefore tests whether Nutex can demonstrate that core patient revenue is scaling fast enough to reduce dependence on arbitration flows — and whether a 21% one-month decline has already priced in the worst of that uncertainty.